Institution
Case Western Reserve University
Education•Cleveland, Ohio, United States•
About: Case Western Reserve University is a education organization based out in Cleveland, Ohio, United States. It is known for research contribution in the topics: Population & Health care. The organization has 54617 authors who have published 106568 publications receiving 5071613 citations. The organization is also known as: Case & Case Western.
Topics: Population, Health care, Cancer, Transplantation, Poison control
Papers published on a yearly basis
Papers
More filters
••
Christina Fitzmaurice1, Christina Fitzmaurice2, Tomi Akinyemiju3, Faris Lami4 +172 more•Institutions (95)
901 citations
••
TL;DR: It is recommended that patients be recruited into ongoing trials, which would provide much needed evidence on the efficacy and safety of various therapies for COVID-19, given that the authors could not make a determination whether the benefits outweigh harms for most treatments.
Abstract: Background There are many pharmacologic therapies that are being used or considered for treatment of COVID-19. There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature. Objective Develop evidence-based rapid guidelines intended to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19. Methods IDSA formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. Process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer-reviewed and grey literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. Results The IDSA guideline panel agreed on 7 treatment recommendations and provided narrative summaries of other treatments undergoing evaluations. Conclusions The panel expressed the overarching goal that patients be recruited into ongoing trials, which would provide much needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments.
897 citations
••
Fox Chase Cancer Center1, University of Utah2, University of Texas MD Anderson Cancer Center3, University of California, San Diego4, University of South Florida5, Brigham and Women's Hospital6, University of Alabama at Birmingham7, Roswell Park Cancer Institute8, Case Western Reserve University9, Ohio State University10, University of Colorado Boulder11, University of Nebraska Medical Center12, Johns Hopkins University13, University of California, San Francisco14, University Of Tennessee System15, City of Hope National Medical Center16, University of Washington17, Duke University18, Northwestern University19, Memorial Sloan Kettering Cancer Center20
TL;DR: This portion of the NCCN Guidelines discusses general principles for the diagnosis, staging, and treatment of STS of the extremities, superficial trunk, or head and neck; outlines treatment recommendations by disease stage; and reviews the evidence to support the guidelines recommendations.
Abstract: Soft tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Guidelines for STS provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as intra-abdominal/retroperitoneal STS, gastrointestinal stromal tumors, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guidelines discusses general principles for the diagnosis, staging, and treatment of STS of the extremities, superficial trunk, or head and neck; outlines treatment recommendations by disease stage; and reviews the evidence to support the guidelines recommendations.
894 citations
01 Jan 2000
TL;DR: Boyatzis and Bar-On as mentioned in this paper presented the Handbook of Emotional Intelligence (HII) for the management of emotional intelligence in organizations, with a focus on organizational behavior.
Abstract: Appeared in Reuven Bar-On and James D.A. Parker (editors)(2000), Handbook of Emotional Intelligence, San Francisco: Jossey-Bass, pages 343-362. Correspondence should be addressed to Richard E. Boyatzis, Department of Organizational Behavior, Weatherhead School of Management, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio, USA, 44106-7235. Reproduced by The Consortium for Research on Emotional Intelligence in Organizations with special permission of the authors.
894 citations
••
Boston Children's Hospital1, University of California, San Diego2, University of California, San Francisco3, Oregon Health & Science University4, Northwestern University5, University of Tennessee Health Science Center6, University of British Columbia7, Children's Memorial Hospital8, New York University9, Case Western Reserve University10, Mayo Clinic11, Wake Forest University12, University of Pennsylvania13, University of Nottingham14, University of Alabama at Birmingham15, Rafael Advanced Defense Systems16, American Academy of Dermatology17, Seattle Children's18
TL;DR: Treatment of atopic dermatitis with nonpharmacologic interventions and pharmacologic topical therapies are reviewed and suggestions on dosing and monitoring are given based on available evidence.
Abstract: Atopic dermatitis is a common and chronic, pruritic inflammatory skin condition that can affect all age groups. This evidence-based guideline addresses important clinical questions that arise in its management. In this second of 4 sections, treatment of atopic dermatitis with nonpharmacologic interventions and pharmacologic topical therapies are reviewed. Where possible, suggestions on dosing and monitoring are given based on available evidence.
889 citations
Authors
Showing all 54953 results
Name | H-index | Papers | Citations |
---|---|---|---|
Robert Langer | 281 | 2324 | 326306 |
Bert Vogelstein | 247 | 757 | 332094 |
Zhong Lin Wang | 245 | 2529 | 259003 |
John Q. Trojanowski | 226 | 1467 | 213948 |
Kenneth W. Kinzler | 215 | 640 | 243944 |
Peter Libby | 211 | 932 | 182724 |
David Baltimore | 203 | 876 | 162955 |
Carlo M. Croce | 198 | 1135 | 189007 |
Ronald Klein | 194 | 1305 | 149140 |
Eric J. Topol | 193 | 1373 | 151025 |
Paul M. Thompson | 183 | 2271 | 146736 |
Yusuke Nakamura | 179 | 2076 | 160313 |
Dennis J. Selkoe | 177 | 607 | 145825 |
David L. Kaplan | 177 | 1944 | 146082 |
Evan E. Eichler | 170 | 567 | 150409 |